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Introduction
There have been enormous strides in the area of renal day symposium on renal bone disease that was held this
summer in Manchester, United Kingdom, as part of anbone diseases in the last decade. These advances have
resulted in a better understanding of the pathogenic annual series in nephrology hosted by the Department
of Renal Medicine at the Manchester Royal Infirmary.mechanisms involved in calcium, phosphate, vitamin D,
Leading researchers with recognized international re-and parathyroid hormone (PTH) interrelationships, and
pute presented the latest developments in pathogenesis,their derangement in chronic renal failure. These mecha-
diagnosis, and management of renal bone disease, clari-nisms have been identified at the level of the parathyroid
fying some of the confusion that existed in the past. Thiscell (vitamin D receptors, calcium-sensing receptors, phos-
is an area that is changing rapidly, and this supplementphate transporters) and PTH gene (gene transcriptions).
reflects the state of the art in our understanding andIn addition, the cellular mechanisms at the level of the
management of renal bone disease as we finish this mil-bone (osteoblast–osteoclast interactions) and resulting
lennium and enter the next. There is an air of optimismhistologic variants have been identified. These new and
that we may now be better able to control the ravages ofexciting developments have had direct therapeutic im-
hyperparathyroidism.Yet much remains unknown, nonepact in managing the clinical syndromes that comprise
more so than the management of osteoporosis in therenal bone disease. Newer agents for managing hyper-
aging ESRD population.parathyroid bone disease (vitamin D analogs, calcimi-
We would like to thank the major sponsors, Baxtermetics) have emerged with potential for better control
Healthcare and Jansen-Cilag, who made the symposiumof hyperparathyroidism. New non-aluminum and non-
possible, and to express our appreciation for the tirelesscalcium containing compounds (Renagel, iron salts, and
work of Diane Comer in the organization of the meetinglanthanum) provide hope that hyperphosphatemia may
and successful compilation of this supplement.be easier to manage. Better insight into other important
areas (osteoporosis, acidosis, b2-microglobulin) may have Ram Gokal, Alastair J. Hutchison, Eberhard Ritz, and
therapeutic possibilities. Eduardo Slatopolsky
Guest EditorsThese and other advances were highlighted in a two-
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